News

The Viaskin Milk patch is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that can deliver biologically active compounds to the immune system through intact skin without

The primary endpoint for the study is the incidence of amenorrhea induced by four months of treatment with two dose levels of Proellex compared to placebo. In addition,

Obizur is indicated to treat bleeding episodes in adult patients with acquired haemophilia caused by antibodies to Factor VIII (FVIII), a life-threatening acute bleeding disorder. It will allow

The trial, called GBM Agile, will test various treatments depending on the molecular profile of a patient’s tumor. Treatments that do not work will be dropped from the

SCY-078 is being developed as both an oral and IV formulation to treat invasive and life-threatening fungal infections including candidemia and invasive aspergillosis. The study will assess the

Of the total amount, the company will spend €5bn for preclinical research through 2020, and €1.5bn will go to collaborations with external partners. The move is intended to

The drug can now be used in patients with genotype 4, 5 and 6 chronic hepatitis C virus (HCV) infection and in patients co-infected with human immunodeficiency virus

AxioMx develops recombinant antibody technologies. The company offers a range of custom antibody discovery and development services for the research, diagnostic and therapeutic marketplaces. Abcam will pay $20m

The round was led by RiverVest Venture Partners, and included investments by New Enterprise Associates, BioMed Ventures and individual investors. Amplyx will use the funding to advance the